Login Register Cart 0
Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies

Author(s): Ankita Singh, Jitendra Kumar and Vijay Kumar*

Volume 23, Issue 18, 2023

Published on: 15 May, 2023

Page: [1727 - 1752] Pages: 26

DOI: 10.2174/1568026623666230413094331

Price: $65

Abstract

The chronic infection of the hepatitis B virus (CHB) represents a major public health problem worldwide. Despite the availability of an effective prophylactic vaccine, millions of hepatitis B patients are at increased risk of developing chronic liver disease. The currently available treatments for HBV infection include interferon and nucleos(t)ide analogues that are effective at suppressing viral load and preventing or delaying the progression of liver disease. However, these treatments offer somewhat unsatisfactory clinical cures due to the persistence of the intrahepatic pool of covalently closed circular DNA (cccDNA) that serves as a reservoir for viral progenies and a potential source of recurring infections. Elimination of viral cccDNA remains a challenge for scientists and pharmaceutical industries in order to achieve the eradication and control of HBV infection. This would involve a detailed understanding of the molecular mechanisms of cccDNA formation, its intracellular stability, and regulation during replication and transcription. Recent advances in drug therapy have heralded a new horizon of novel therapeutic approaches for CHB infection, with several promising antiviral and immunomodulatory agents currently in preclinical or clinical testing. However, approval of any new curative therapy would involve rigorous evaluation of the efficacy and safety of each treatment and defining correct endpoints associated with improved clinical outcomes. This article summarizes the current landscape of HBV treatments, and drugs in clinical trials and highlights the most recent anti-HBV small molecules designed to directly target HBV or to improve immune response during chronic infection.

« Previous Next »
Graphical Abstract

[1]
WHO. Key facts Hepatitis B. 2021. Available From: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
[2]
WHO. Global hepatitis report. 2017. Available From: https://www.who.int/publications/i/item/9789241565455
[3]
Naggie, S.; Lok, A.S. New Therapeutics for Hepatitis B: The Road to Cure. Annu. Rev. Med., 2021, 72(1), 93-105.
[http://dx.doi.org/10.1146/annurev-med-080119-103356] [PMID: 33085923]
[4]
Lok, A.S.F.; McMahon, B.J. Chronic hepatitis B. Hepatology, 2007, 45(2), 507-539.
[http://dx.doi.org/10.1002/hep.21513] [PMID: 17256718]
[5]
Kwon, H.; Lok, A.S. Hepatitis B therapy. Nat. Rev. Gastroenterol. Hepatol., 2011, 8(5), 275-284.
[http://dx.doi.org/10.1038/nrgastro.2011.33] [PMID: 21423260]
[6]
Lamontagne, R.J.; Bagga, S.; Bouchard, M.J. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res., 2016, 2(7), 163-186.
[http://dx.doi.org/10.20517/2394-5079.2016.05] [PMID: 28042609]
[7]
Seeger, C.; Mason, W.S. Molecular biology of hepatitis B virus infection. Virology, 2015, 479-480, 672-686.
[http://dx.doi.org/10.1016/j.virol.2015.02.031] [PMID: 25759099]
[8]
Summers, J.; Mason, W.S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell, 1982, 29(2), 403-415.
[http://dx.doi.org/10.1016/0092-8674(82)90157-X] [PMID: 6180831]
[9]
Ganem, D.; Prince, A.M. Hepatitis B virus infection--natural history and clinical consequences. N. Engl. J. Med., 2004, 350(11), 1118-1129.
[http://dx.doi.org/10.1056/NEJMra031087] [PMID: 15014185]
[10]
Ringehan, M.; McKeating, J.A.; Protzer, U. Viral hepatitis and liver cancer. Philos. Trans. R. Soc. Lond. B Biol. Sci., 2017, 372(1732), 20160274.
[http://dx.doi.org/10.1098/rstb.2016.0274] [PMID: 28893941]
[11]
Li, W.; Urban, S. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J. Hepatol., 2016, 64(1)(Suppl.), S32-S40.
[http://dx.doi.org/10.1016/j.jhep.2016.02.011] [PMID: 27084034]
[12]
Yan, H.; Zhong, G.; Xu, G.; He, W.; Jing, Z.; Gao, Z.; Huang, Y.; Qi, Y.; Peng, B.; Wang, H.; Fu, L.; Song, M.; Chen, P.; Gao, W.; Ren, B.; Sun, Y.; Cai, T.; Feng, X.; Sui, J.; Li, W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife, 2012, 1e00049
[http://dx.doi.org/10.7554/eLife.00049] [PMID: 23150796]
[13]
Baumert, T.F.; Meredith, L.; Ni, Y.; Felmlee, D.J.; McKeating, J.A.; Urban, S. Entry of hepatitis B and C viruses — recent progress and future impact. Curr. Opin. Virol., 2014, 4, 58-65.
[http://dx.doi.org/10.1016/j.coviro.2013.12.002] [PMID: 24418809]
[14]
Wei, L.; Ploss, A. Mechanism of Hepatitis B Virus cccDNA Formation. Viruses, 2021, 13(8), 1463.
[http://dx.doi.org/10.3390/v13081463] [PMID: 34452329]
[15]
Tong, S.; Revill, P. Overview of hepatitis B viral replication and genetic variability. J. Hepatol., 2016, 64(1)(Suppl.), S4-S16.
[http://dx.doi.org/10.1016/j.jhep.2016.01.027] [PMID: 27084035]
[16]
Koumbi, L.; Karayiannis, P. The epigenetic control of hepatitis B virus modulates the outcome of infection. Front Microbiol., 6, 1491, 2016.
[http://dx.doi.org/10.3389/fmicb.2015.01491]
[17]
Kumar, V.; Sarkar, D.P.; Hepatitis, B. Virus X protein (HBx): Structure-function relationships and role in viral pathogenesis. Handb. Exp. Pharmacol., 2004, 166, 377-407.
[http://dx.doi.org/10.1007/978-3-642-18932-6_12]
[18]
Slagle, B.L.; Bouchard, M.J.; Hepatitis, B. Hepatitis B virus X and regulation of viral gene expression. Cold Spring Harb. Perspect. Med., 2016, 6(3)a021402
[http://dx.doi.org/10.1101/cshperspect.a021402] [PMID: 26747833]
[19]
Liu, S.; Koh, S.; Lee, C.; Hepatitis, B.; Virus, X. Protein and Hepatocarcinogenesis. Int. J. Mol. Sci., 2016, 17(6), 940.
[http://dx.doi.org/10.3390/ijms17060940] [PMID: 27314335]
[20]
Murphy, C.M.; Xu, Y.; Li, F.; Nio, K.; Reszka-Blanco, N.; Li, X.; Wu, Y.; Yu, Y.; Xiong, Y.; Su, L.; Hepatitis, B.; Virus, X. Hepatitis B Virus X protein promotes degradation of SMC5/6 to enhance HBV replication. Cell Rep., 2016, 16(11), 2846-2854.
[http://dx.doi.org/10.1016/j.celrep.2016.08.026] [PMID: 27626656]
[21]
Mohebbi, A.; Lorestani, N.; Tahamtan, A.; Kargar, N.L.; Tabarraei, A. An overview of Hepatitis B virus surface antigen secretion inhibitors. Front. Microbiol., 2018, 9, 662.
[http://dx.doi.org/10.3389/fmicb.2018.00662] [PMID: 29675010]
[22]
Stavrou, S.; Ross, S.R. APOBEC3 proteins in viral immunity. J. Immunol., 2015, 195(10), 4565-4570.
[http://dx.doi.org/10.4049/jimmunol.1501504] [PMID: 26546688]
[23]
Niklasch, M.; Zimmermann, P.; Nassal, M. The hepatitis B virus nucleocapsid-Dynamic compartment for infectious virus production and new antiviral target. Biomedicines, 2021, 9(11), 1577.
[http://dx.doi.org/10.3390/biomedicines9111577] [PMID: 34829806]
[24]
Jiang, B.; Hildt, E. Intracellular trafficking of HBV particles. Cells, 2020, 9(9), 2023.
[http://dx.doi.org/10.3390/cells9092023] [PMID: 32887393]
[25]
Selzer, L.; Zlotnick, A. Assembly and release of hepatitis B virus. Cold Spring Harb. Perspect. Med., 2015, 5(12)a021394
[http://dx.doi.org/10.1101/cshperspect.a021394] [PMID: 26552701]
[26]
Meng, Z.; Chen, Y.; Lu, M. Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection. Front. Immunol., 2020, 10, 3127.
[http://dx.doi.org/10.3389/fimmu.2019.03127] [PMID: 32117201]
[27]
Caligiuri, P.; Cerruti, R.; Icardi, G.; Bruzzone, B. Overview of hepatitis B virus mutations and their implications in the management of infection. World J. Gastroenterol., 2016, 22(1), 145-154.
[http://dx.doi.org/10.3748/wjg.v22.i1.145] [PMID: 26755866]
[28]
Chang, M.H.; Chen, D.S. Prevention of hepatitis B. Cold Spring Harb. Perspect. Med., 2015, 5(3)a021493
[http://dx.doi.org/10.1101/cshperspect.a021493] [PMID: 25732034]
[29]
Doong, S.L.; Tsai, C.H.; Schinazi, R.F.; Liotta, D.C.; Cheng, Y.C. Inhibition of the replication of hepatitis B virus in vitroby 2′3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA, 1991, 88(19), 8495-8499.
[http://dx.doi.org/10.1073/pnas.88.19.8495] [PMID: 1656445]
[30]
Dienstag, J.L.; Perrillo, R.P.; Schiff, E.R.; Bartholomew, M.; Vicary, C.; Rubin, M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med., 1995, 333(25), 1657-1661.
[http://dx.doi.org/10.1056/NEJM199512213332501] [PMID: 7477217]
[31]
Dienstag, J.L.; Wei, L.J.; Xu, D.; Kreter, B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin. Drug Investig., 2007, 27(1), 35-49.
[http://dx.doi.org/10.2165/00044011-200727010-00003] [PMID: 17177578]
[32]
Tassopoulos, N.C.; Volpes, R.; Pastore, G.; Heathcote, J.; Buti, M.; Goldin, R.D.; Hawley, S.; Barber, J.; Condreay, L.; Gray, D.F. Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis BB. Hepatology, 1999, 29(3), 889-896.
[http://dx.doi.org/10.1002/hep.510290321] [PMID: 10051494]
[33]
Yang, H.; Westland, C.E.; Delaney, W.E., IV; Heathcote, E.J.; Ho, V.; Fry, J.; Brosgart, C.; Gibbs, C.S.; Miller, M.D.; Xiong, S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology, 2002, 36(2), 464-473.
[http://dx.doi.org/10.1053/jhep.2002.34740] [PMID: 12143057]
[34]
Lok, A.S.F.; Lai, C.L.; Leung, N.; Yao, G.B.; Cui, Z.Y.; Schiff, E.R.; Dienstag, J.L.; Heathcote, E.J.; Little, N.R.; Griffiths, D.A.; Gardner, S.D.; Castiglia, M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003, 125(6), 1714-1722.
[http://dx.doi.org/10.1053/j.gastro.2003.09.033] [PMID: 14724824]
[35]
Ono-Nita, S.K.; Kato, N.; Shiratori, Y.; Masaki, T.; Lan, K.H.; Carrilho, F.J.; Omata, M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study byin vitrofull-length viral DNA transfection. Hepatology, 1999, 29(3), 939-945.
[http://dx.doi.org/10.1002/hep.510290340] [PMID: 10051501]
[36]
Wang, H-L.; Lu, X.; Yang, X.; Xu, N. Antiviraxients: A systematic review and network meta-analysis. Gastroenterol. Res. Pract., 2016, 2016, 1-10.
[http://dx.doi.org/10.1155/2016/3435965]
[37]
Charuworn, P.; Keeffe, E.B. A review of the use of telbivudine in the treatment of chronic hepatitis B. B. Clin. Med. Ther., 2009, 1, CMT.S2321.
[http://dx.doi.org/10.4137/CMT.S2321]
[38]
Keam, S.J. Telbivudine. Drugs, 2007, 67(13), 1917-1929.
[http://dx.doi.org/10.2165/00003495-200767130-00011] [PMID: 17722961]
[39]
Buster, E.H.C.J.; Flink, H.J.; Cakaloglu, Y.; Simon, K.; Trojan, J.; Tabak, F.; So, T.M.K.; Feinman, S.V.; Mach, T.; Akarca, U.S.; Schutten, M.; Tielemans, W.; van Vuuren, A.J.; Hansen, B.E.; Janssen, H.L.A. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology, 2008, 135(2), 459-467.
[http://dx.doi.org/10.1053/j.gastro.2008.05.031] [PMID: 18585385]
[40]
Innaimo, S.F.; Seifer, M.; Bisacchi, G.S.; Standring, D.N.; Zahler, R.; Colonno, R.J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother., 1997, 41(7), 1444-1448.
[http://dx.doi.org/10.1128/AAC.41.7.1444] [PMID: 9210663]
[41]
Scott, L.J.; Keating, G.M. Entecavir. Drugs, 2009, 69(8), 1003-1033.
[http://dx.doi.org/10.2165/00003495-200969080-00005] [PMID: 19496629]
[42]
Asselah, T.; Lada, O.; Moucari, R.; Marcellin, P. Clevudine: A promising therapy for the treatment of chronic hepatitis B. Expert Opin. Investig. Drugs, 2008, 17(12), 1963-1974.
[http://dx.doi.org/10.1517/13543780802535760] [PMID: 19012511]
[43]
Jang, J.H.; Kim, J.W.; Jeong, S.H.; Myung, H.J.; Kim, H.S.; Park, Y.S.; Lee, S.H.; Hwang, J.H.; Kim, N.; Lee, D.H. Clevudine for chronic hepatitis B: Antiviral response, predictors of response, and development of myopathy. J. Viral Hepat., 2011, 18(2), 84-90.
[http://dx.doi.org/10.1111/j.1365-2893.2010.01281.x] [PMID: 20196804]
[44]
Dando, T.M.; Plosker, G.L. Adefovir Dipivoxil. Drugs, 2003, 63(20), 2215-2234.
[http://dx.doi.org/10.2165/00003495-200363200-00007] [PMID: 14498759]
[45]
Hadziyannis, S.J.; Tassopoulos, N.C.; Heathcote, E.J.; Chang, T.T.; Kitis, G.; Rizzetto, M.; Marcellin, P.; Lim, S.G.; Goodman, Z.; Ma, J.; Brosgart, C.L.; Borroto-Esoda, K.; Arterburn, S.; Chuck, S.L. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 2006, 131(6), 1743-1751.
[http://dx.doi.org/10.1053/j.gastro.2006.09.020] [PMID: 17087951]
[46]
Clercq, E.D.; Holý, A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat. Rev. Drug Discov., 2005, 4(11), 928-940.
[http://dx.doi.org/10.1038/nrd1877] [PMID: 16264436]
[47]
Balzarini, J.; Holy, A.; Jindrich, J.; Naesens, L.; Snoeck, R.; Schols, D.; De Clercq, E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitroand in vivoantiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother., 1993, 37(2), 332-338.
[http://dx.doi.org/10.1128/AAC.37.2.332] [PMID: 8452366]
[48]
Perry, C.M.; Simpson, D. Tenofovir disoproxil fumarate: In chronic hepatitis B. Drugs, 2009, 69(16), 2245-2256.
[http://dx.doi.org/10.2165/10482940-000000000-00000] [PMID: 19852527]
[49]
Charlton, M.R.; Alam, A.; Shukla, A.; Dashtseren, B.; Lesmana, C.R.A.; Duger, D.; Payawal, D.A.; Duy Cuong, D.; Jargalsaikhan, G.; Cua, I.H.Y.; Sollano, J.D.; Singh, K.R.; Madan, K.; Win, K.M.; Kyi, K.P.; Tun, K.S.; Salih, M.; Rastogi, M.; Saraf, N.; Thuy, P.T.T.; Hien, P.T.D.; Gani, R.A.; Mohamed, R.; Tanwandee, T.; Piratvisuth, T.; Sukeepaisarnjaroen, W.; Naing, W.; Hashmi, Z.Y. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J. Gastroenterol., 2020, 55(9), 811-823.
[http://dx.doi.org/10.1007/s00535-020-01698-4] [PMID: 32666200]
[50]
Lin, F.; Young, H.A. Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev., 2014, 25(4), 369-376.
[http://dx.doi.org/10.1016/j.cytogfr.2014.07.015] [PMID: 25156421]
[51]
Brunetto, M.R.; Bonino, F. Interferon therapy of chronic hepatitis B. Intervirology, 2014, 57(3-4), 163-170.
[http://dx.doi.org/10.1159/000360941] [PMID: 25034484]
[52]
Arends, J.E.; Lieveld, F.I.; Ahmad, S.; Ustianowski, A. New viral and immunological targets for hepatitis B treatment and cure: A review. Infect. Dis. Ther., 2017, 6(4), 461-476.
[http://dx.doi.org/10.1007/s40121-017-0173-y] [PMID: 29071665]
[53]
Painter, G.R.; Almond, M.R.; Trost, L.C.; Lampert, B.M.; Neyts, J.; De Clercq, E.; Korba, B.E.; Aldern, K.A.; Beadle, J.R.; Hostetler, K.Y. Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob. Agents Chemother., 2007, 51(10), 3505-3509.
[http://dx.doi.org/10.1128/AAC.00460-07] [PMID: 17646420]
[54]
Lai, C.L.; Ahn, S.H.; Lee, K.S.; Um, S.H.; Cho, M.; Yoon, S.K.; Lee, J.W.; Park, N.H.; Kweon, Y.O.; Sohn, J.H.; Lee, J.; Kim, J.A.; Han, K.H.; Yuen, M.F. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut, 2014, 63(6), 996-1004.
[http://dx.doi.org/10.1136/gutjnl-2013-305138] [PMID: 23979965]
[55]
Lv, Z.; He, W.; Tian, W.; Kang, J.; Liu, Y.; Peng, Y.; Zheng, L.; Wang, Q.; Yu, W.; Chang, J. Design, synthesis, and biological evaluation of new N4-Substituted 2′-deoxy-2′-fluoro-4′-azido cytidine derivatives as potent anti-HBV agents. Eur. J. Med. Chem., 2015, 101-, 103-110.
[http://dx.doi.org/10.1016/j.ejmech.2015.06.030]
[56]
Ren, Q.; Liu, X.; Luo, Z.; Li, J.; Wang, C.; Goldmann, S.; Zhang, J.; Zhang, Y. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). Bioorg. Med. Chem., 2017, 25(3), 1042-1056.
[http://dx.doi.org/10.1016/j.bmc.2016.12.017] [PMID: 28082068]
[57]
Wang, C.; Pei, Y.; Wang, L.; Li, S.; Jiang, C.; Tan, X.; Dong, Y.; Xiang, Y.; Ma, Y.; Liu, G. Discovery of (1 H -Pyrazolo[3,4-c]pyridin-5-yl)sulfonamide analogues as hepatitis B virus capsid assembly modulators by conformation constraint. J. Med. Chem., 2020, 63(11), 6066-6089.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00292] [PMID: 32421339]
[58]
Yuen, M.F.; Gane, E.J.; Kim, D.J.; Weilert, F.; Yuen, Chan H.L.; Lalezari, J.; Hwang, S.G.; Nguyen, T.; Flores, O.; Hartman, G.; Liaw, S.; Lenz, O.; Kakuda, T.N.; Talloen, W.; Schwabe, C.; Klumpp, K.; Brown, N. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology, 2019, 156(5), 1392-1403.e7.
[http://dx.doi.org/10.1053/j.gastro.2018.12.023] [PMID: 30625297]
[59]
Kakuda, T.; Bene, F.D.; Yuen, M-F.; Gone, E.J.; Kim, S.; Liaw, S.; Brown, N.; Klumpp, K.; Flores, L.; Chanda, S. Pharmacokinetics (PK) and PK modeling of the first-in- class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients with chronic HBV infection (CHBV). Hepatology, 2016, 64, 931A.
[http://dx.doi.org/10.1002/hep.28800]
[60]
Huang, Q.; Cai, D.; Yan, R.; Li, L.; Zong, Y.; Guo, L.; Mercier, A.; Zhou, Y.; Tang, A.; Henne, K.; Colonno, R. Preclinical profile and characterization of the hepatitis b virus core protein inhibitor abi-h0731. Antimicrob. Agents Chemother., 2020, 64(11), e01463-e20.
[http://dx.doi.org/10.1128/AAC.01463-20] [PMID: 32868329]
[61]
Yuen, M.F.; Agarwal, K.; Gane, E.J.; Schwabe, C.; Ahn, S.H.; Kim, D.J.; Lim, Y.S.; Cheng, W.; Sievert, W.; Visvanathan, K.; Ruby, E.; Liaw, S.; Yan, R.; Huang, Q.; Colonno, R.; Lopatin, U. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: A randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol. Hepatol., 2020, 5(2), 152-166.
[http://dx.doi.org/10.1016/S2468-1253(19)30346-2] [PMID: 31711752]
[62]
Vaine, M.; Dellisola, V.; Clugston, S.; Cao, H.; Gao, X.; Kass, J.; Li, W.; Peng, X.; Qiu, Y.L.; Jiang, L.; Daniels, K.; Or, Y.S.; Goodwin, B.; Lin, K. FRI-191-EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo. J. Hepatol., 2019, 70(1), e474-e475.
[http://dx.doi.org/10.1016/S0618-8278(19)30936-3]
[63]
Zoulim, F.; Lenz, O.; Vandenbossche, J.J.; Talloen, W.; Verbinnen, T.; Moscalu, I.; Streinu-Cercel, A.; Bourgeois, S.; Buti, M.; Crespo, J.; Manuel Pascasio, J.; Sarrazin, C.; Vanwolleghem, T.; Shukla, U.; Fry, J.; Yogaratnam, J.Z. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology, 2020, 159(2), 521-533.e9.
[http://dx.doi.org/10.1053/j.gastro.2020.04.036] [PMID: 32343960]
[64]
Berke, J.M.; Dehertogh, P.; Vergauwen, K.; Mostmans, W.; Vandyck, K.; Raboisson, P.; Pauwels, F. Antiviral properties and mechanism of action studies of the hepatitis b virus capsid assembly modulator JNJ-56136379. Antimicrob. Agents Chemother., 2020, 64(5), e02439-e19.
[http://dx.doi.org/10.1128/AAC.02439-19] [PMID: 32094138]
[65]
Berke, J.M.; Dehertogh, P.; Vergauwen, K.; Verbinnen, T.; Vendeville, S.; Raboisson, P.; Pauwels, F. In vitro antiviral activity and mode of action of JNJ-64530440, a novel potent hepatitis B virus capsid assembly modulator in clinical development. Hepatology, 2018, 2018(68)(Suppl. 1), 239A.
[66]
Kakuda, T.N.; Yogaratnam, J.Z.; Westland, C.; Gane, E.J.; Schwabe, C.; Vuong, J.; Patel, M.; Snoeys, J.; Talloen, W.; Lenz, O.; Fry, J.; Chanda, S.; van Remoortere, P. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antivir. Ther., 2021, 26(1-2), 13-24.
[http://dx.doi.org/10.1177/13596535211044331] [PMID: 35485346]
[67]
Gane, E.J.; Schwabe, C.; Berliba, E.; Tangkijvanich, P.; Jucov, A.; Ghicavii, N.; Verbinnen, T.; Lenz, O.; Talloen, W.; Kakuda, T.N.; Westland, C.; Patel, M.; Yogaratnam, J.Z.; Dragone, L.; Van Remoortere, P. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J. Antimicrob. Chemother., 2022, 77(4), 1102-1110.
[http://dx.doi.org/10.1093/jac/dkab491] [PMID: 35040959]
[68]
Cosson, V.; Feng, S.; Jaminion, F.; Lemenuel-Diot, A.; Parrott, N.; Paehler, A.; Bo, Q.; Jin, Y. How Semiphysiological Population Pharmacokinetic Modeling Incorporating active hepatic uptake supports phase ii dose selection of ro7049389, a novel anti–hepatitis B virus drug. Clin. Pharmacol. Ther., 2021, 109(4), 1081-1091.
[http://dx.doi.org/10.1002/cpt.2184] [PMID: 33523474]
[69]
Yuen, M.F.; Zhou, X.; Gane, E.; Schwabe, C.; Tanwandee, T.; Feng, S.; Jin, Y.; Triyatni, M.; Lemenuel-Diot, A.; Cosson, V.; Xue, Z.; Kazma, R.; Bo, Q. Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: A multicentre, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol. Hepatol., 2021, 6(9), 723-732.
[http://dx.doi.org/10.1016/S2468-1253(21)00176-X] [PMID: 34237271]
[70]
Xia, Y.; Liang, T.J. Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection. Gastroenterology, 2019, 156(2), 311-324.
[http://dx.doi.org/10.1053/j.gastro.2018.07.057] [PMID: 30243618]
[71]
Zhao, N.; Jia, B.; Zhao, H.; Xu, J.; Sheng, X.; Luo, L.; Huang, Z.; Wang, X.; Ren, Q.; Zhang, Y.; Zhao, X.; Cui, Y. A first-in-human trial of GLS4, a novel inhibitor of hepatitis b virus capsid assembly, following single- and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers. Antimicrob. Agents Chemother., 2019, 64(1), e01686-e19.
[http://dx.doi.org/10.1128/AAC.01686-19] [PMID: 31636065]
[72]
Zhang, H.; Wang, F.; Zhu, X.; Chen, Y.; Chen, H.; Li, X.; Wu, M.; Li, C.; Liu, J.; Zhang, Y.; Ding, Y.; Niu, J. Antiviral activity and pharmacokinetics of the hepatitis B Virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection. Clin. Infect. Dis., 2021, 73(2), 175-182.
[http://dx.doi.org/10.1093/cid/ciaa961] [PMID: 32649736]
[73]
Yang, L.; Shi, L.; Chen, H.; Tong, X.K.; Wang, G.; Zhang, Y.; Wang, W.; Feng, C.; He, P.; Zhu, F.; Hao, Y.; Wang, B.; Yang, D.; Tang, W.; Nan, F.; Zuo, J. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol. Sin., 2014, 35(3), 410-418.
[http://dx.doi.org/10.1038/aps.2013.175] [PMID: 24487969]
[74]
Wang, Y.J.; Lu, D.; Xu, Y.B.; Xing, W.Q.; Tong, X.K.; Wang, G.F.; Feng, C.L.; He, P.L.; Yang, L.; Tang, W.; Hu, Y.H.; Zuo, J.P. A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation. Antimicrob. Agents Chemother., 2015, 59(11), 7061-7072.
[http://dx.doi.org/10.1128/AAC.01558-15] [PMID: 26349829]
[75]
Kang, J.A.; Kim, S.; Park, M.; Park, H.J.; Kim, J.H.; Park, S.; Hwang, J.R.; Kim, Y.C.; Jun Kim, Y.; Cho, Y.; Sun, Jin M.; Park, S.G. Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly. Nat. Commun., 2019, 10(1), 2184.
[http://dx.doi.org/10.1038/s41467-019-10200-5] [PMID: 31097716]
[76]
Kaneko, M.; Watashi, K.; Kamisuki, S.; Matsunaga, H.; Iwamoto, M.; Kawai, F.; Ohashi, H.; Tsukuda, S.; Shimura, S.; Suzuki, R.; Aizaki, H.; Sugiyama, M.; Park, S.Y.; Ito, T.; Ohtani, N.; Sugawara, F.; Tanaka, Y.; Mizokami, M.; Sureau, C.; Wakita, T. A novel tricyclic polyketide, vanitaracin a, specifically inhibits the entry of hepatitis b and d viruses by targeting sodium taurocholate cotransporting polypeptide. J. Virol., 2015, 89(23), 11945-11953.
[http://dx.doi.org/10.1128/JVI.01855-15] [PMID: 26378168]
[77]
Nkongolo, S.; Ni, Y.; Lempp, F.A.; Kaufman, C.; Lindner, T.; Esser-Nobis, K.; Lohmann, V.; Mier, W.; Mehrle, S.; Urban, S. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J. Hepatol., 2014, 60(4), 723-731.
[http://dx.doi.org/10.1016/j.jhep.2013.11.022] [PMID: 24295872]
[78]
Watashi, K.; Sluder, A.; Daito, T.; Matsunaga, S.; Ryo, A.; Nagamori, S.; Iwamoto, M.; Nakajima, S.; Tsukuda, S.; Borroto-Esoda, K.; Sugiyama, M.; Tanaka, Y.; Kanai, Y.; Kusuhara, H.; Mizokami, M.; Wakita, T. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology, 2014, 59(5), 1726-1737.
[http://dx.doi.org/10.1002/hep.26982] [PMID: 24375637]
[79]
Wang, X.; Hu, W.; Zhang, T.; Mao, Y.; Liu, N.; Wang, S. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+-dependent taurocholate cotransporting polypeptide activity. Antiviral Res., 2015, 120, 140-146.
[http://dx.doi.org/10.1016/j.antiviral.2015.06.007] [PMID: 26086883]
[80]
Lucifora, J.; Esser, K.; Protzer, U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res., 2013, 97(2), 195-197.
[http://dx.doi.org/10.1016/j.antiviral.2012.12.008] [PMID: 23266293]
[81]
Tsukuda, S.; Watashi, K.; Hojima, T.; Isogawa, M.; Iwamoto, M.; Omagari, K.; Suzuki, R.; Aizaki, H.; Kojima, S.; Sugiyama, M.; Saito, A.; Tanaka, Y.; Mizokami, M.; Sureau, C.; Wakita, T. A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. Hepatology, 2017, 65(4), 1104-1116.
[http://dx.doi.org/10.1002/hep.28952] [PMID: 27863453]
[82]
Volz, T. Allweiss, L.; ḾBarek, M.B.; Warlich, M.; Lohse, A.W.; Pollok, J.M.; Alexandrov, A.; Urban, S.; Petersen, J.; Lütgehetmann, M.; Dandri, M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J. Hepatol., 2013, 58(5), 861-867.
[http://dx.doi.org/10.1016/j.jhep.2012.12.008] [PMID: 23246506]
[83]
Urban, S.; Bartenschlager, R.; Kubitz, R.; Zoulim, F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology, 2014, 147(1), 48-64.
[http://dx.doi.org/10.1053/j.gastro.2014.04.030] [PMID: 24768844]
[84]
Bogomolov, P.; Alexandrov, A.; Voronkova, N.; Macievich, M.; Kokina, K.; Petrachenkova, M.; Lehr, T.; Lempp, F.A.; Wedemeyer, H.; Haag, M.; Schwab, M.; Haefeli, W.E.; Blank, A.; Urban, S. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J. Hepatol., 2016, 65(3), 490-498.
[http://dx.doi.org/10.1016/j.jhep.2016.04.016] [PMID: 27132170]
[85]
Hu, Y. Cheng, X.; Cao, F.; Huang, A.; Tavis, J.E. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res., 2013, 99(3), 221-229.
[http://dx.doi.org/10.1016/j.antiviral.2013.06.007] [PMID: 23796982]
[86]
Tavis, J.E.; Zoidis, G.; Meyers, M.J.; Murelli, R.P. Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H. ACS Infect. Dis., 2019, 5(5), 655-658.
[http://dx.doi.org/10.1021/acsinfecdis.8b00045] [PMID: 29565562]
[87]
Ghosh, S.; Kaushik, A.; Khurana, S.; Varshney, A.; Singh, A.K.; Dahiya, P.; Thakur, J.K.; Sarin, S.K.; Gupta, D.; Malhotra, P.; Mukherjee, S.K.; Bhatnagar, R.K. An RNAi-based high-throughput screening assay to identify small molecule inhibitors of hepatitis B virus replication. J. Biol. Chem., 2017, 292(30), 12577-12588.
[http://dx.doi.org/10.1074/jbc.M117.775155] [PMID: 28584057]
[88]
Sekiba, K.; Otsuka, M.; Ohno, M.; Yamagami, M.; Kishikawa, T.; Suzuki, T.; Ishibashi, R.; Seimiya, T.; Tanaka, E.; Koike, K. Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx–DDB1 Interaction. Cell. Mol. Gastroenterol. Hepatol., 2019, 7(2), 297-312.
[http://dx.doi.org/10.1016/j.jcmgh.2018.10.010] [PMID: 30704981]
[89]
Mishra, S.; Pandey, A.; Manvati, S. Coumarin: An emerging antiviral agent. Heliyon, 2020, 6(1)e03217
[http://dx.doi.org/10.1016/j.heliyon.2020.e03217] [PMID: 32042967]
[90]
Cheng, S.T.; Hu, J.L.; Ren, J.H.; Yu, H.B.; Zhong, S.; Wai Wong, V.K.; Kwan Law, B.Y.; Chen, W.X.; Xu, H.M.; Zhang, Z.Z.; Cai, X.F.; Hu, Y.; Zhang, W.L.; Long, Q.X.; Ren, F.; Zhou, H.Z.; Huang, A.L.; Chen, J. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx. J. Hepatol., 2021, 74(3), 522-534.
[http://dx.doi.org/10.1016/j.jhep.2020.09.019] [PMID: 32987030]
[91]
Roehl, I.; Seiffert, S.; Brikh, C.; Quinet, J.; Jamard, C.; Dorfler, N.; Lockridge, J.A.; Cova, L.; Vaillant, A. Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy. Mol. Ther. Nucleic Acids, 2017, 8, 1-12.
[http://dx.doi.org/10.1016/j.omtn.2017.04.019] [PMID: 28918011]
[92]
Quinet, J.; Jamard, C.; Burtin, M.; Lemasson, M.; Guerret, S.; Sureau, C.; Vaillant, A.; Cova, L. Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks. Hepatology, 2018, 67(6), 2127-2140.
[http://dx.doi.org/10.1002/hep.29737] [PMID: 29251788]
[93]
Bazinet, M.; Pântea, V.; Placinta, G.; Moscalu, I.; Cebotarescu, V.; Cojuhari, L.; Jimbei, P.; Iarovoi, L.; Smesnoi, V.; Musteata, T.; Jucov, A.; Dittmer, U.; Krawczyk, A.; Vaillant, A. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology, 2020, 158(8), 2180-2194.
[http://dx.doi.org/10.1053/j.gastro.2020.02.058] [PMID: 32147484]
[94]
Bazinet, M.; Pântea, V.; Cebotarescu, V.; Cojuhari, L.; Jimbei, P.; Anderson, M.; Gersch, J.; Holzmayer, V.; Elsner, C.; Krawczyk, A.; Kuhns, M.C.; Cloherty, G.; Dittmer, U.; Vaillant, A. Persistent control of hepatitis B virus and hepatitis delta virus infection following rep 2139-ca and pegylated interferon therapy in chronic hepatitis b virus/hepatitis delta virus coinfection. Hepatol. Commun., 2021, 5(2), 189-202.
[http://dx.doi.org/10.1002/hep4.1633] [PMID: 33553968]
[95]
Yu, W.; Goddard, C.; Clearfield, E.; Mills, C.; Xiao, T.; Guo, H.; Morrey, J.D.; Motter, N.E.; Zhao, K.; Block, T.M.; Cuconati, A.; Xu, X. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J. Med. Chem., 2011, 54(16), 5660-5670.
[http://dx.doi.org/10.1021/jm200696v] [PMID: 21786803]
[96]
Xu, Y.B.; Yang, L.; Wang, G.F.; Tong, X.K.; Wang, Y.J.; Yu, Y.; Jing, J.F.; Feng, C.L.; He, P.L.; Lu, W.; Tang, W.; Zuo, J.P. Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion. Antiviral Res., 2014, 107, 6-15.
[http://dx.doi.org/10.1016/j.antiviral.2014.04.002] [PMID: 24746457]
[97]
Han, X.; Javanbakht, H.; Jiang, M.; Liang, C.; Wang, J.; Wang, Y.; Wang, Z.; Weikert, R.J.; Yang, S.; Zhou, C. US9458153, 2015.
[98]
Wildum, S.; Steiner, G.; Luangsay, S.; Suresh, M.; Korolowicz, K.; Balarezo, M.; Yon, C.; Murreddu, M.; Hong, X.; Kallakury, B.; Tucker, R.; Mueller, H.; Menne, S.; Young, J.; Javanbakht, H. Antiviral efficacy of a novel hepatitis B virus expression inhibitor in combination with entecavir and wIFN-alpha in woodchucks model of chronic hepatitis B. J. Hepatol., 2017, 66(1), S693.
[http://dx.doi.org/10.1016/S0168-8278(17)31861-5]
[99]
Lee, H.W.; Park, J.Y.; Hong, T.; Park, M.S.; Ahn, S.H. Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection. Clin. Gastroenterol. Hepatol., 2020, 18(13), 3043-3045.e1.
[http://dx.doi.org/10.1016/j.cgh.2019.09.038] [PMID: 31589980]
[100]
Guo, J.; Chang, J.; Block, T.M.; Kinney, W.A.; Almond, H.R. Almond, modulation of hepatitis B virus cccDNA transcription. US10143720B2, 2018.
[101]
Ying, C.; Li, Y.; Leung, C.H.; Robek, M.D.; Cheng, Y.C. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc. Natl. Acad. Sci. USA, 2007, 104(20), 8526-8531.
[http://dx.doi.org/10.1073/pnas.0609883104] [PMID: 17488817]
[102]
Janmanchi, D.; Tseng, Y.P.; Wang, K.C.; Huang, R.L.; Lin, C.H.; Yeh, S.F. Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents. Bioorg. Med. Chem., 2010, 18(3), 1213-1226.
[http://dx.doi.org/10.1016/j.bmc.2009.12.038] [PMID: 20061158]
[103]
Ying, C.; Tan, S.; Cheng, Y.C. Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. Antivir. Chem. Chemother., 2010, 21(2), 97-103.
[http://dx.doi.org/10.3851/IMP1686] [PMID: 21107018]
[104]
Wang, L.J.; Geng, C.A.; Ma, Y.B.; Luo, J.; Huang, X.Y.; Chen, H.; Zhou, N.J.; Zhang, X.M.; Chen, J.J. Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents. Eur. J. Med. Chem., 2012, 54, 352-365.
[http://dx.doi.org/10.1016/j.ejmech.2012.05.012] [PMID: 22687441]
[105]
Huang, Q.; Huang, R.; Wei, L.; Chen, Y.; Lv, S.; Liang, C.; Zhang, X.; Yin, F.; Li, H.; Zhuo, L.; Lin, X. Antiviral activity of methyl helicterate isolated from Helicteres angustifolia (Sterculiaceae) against hepatitis B virus. Antiviral Res., 2013, 100(2), 373-381.
[http://dx.doi.org/10.1016/j.antiviral.2013.09.007] [PMID: 24055834]
[106]
Huang, Q.; Zhang, S.; Huang, R.; Wei, L.; Chen, Y.; Lv, S.; Liang, C.; Tan, S. liang, S.; Zhuo, L.; Lin, X. Isolation and identification of an anti-hepatitis B virus compound from Hydrocotyle sibthorpioides Lam. J. Ethnopharmacol., 2013, 150(2), 568-575.
[http://dx.doi.org/10.1016/j.jep.2013.09.009] [PMID: 24051027]
[107]
Wu, Y-H.; Hao, B-J.; Cao, H-C.; Xu, W.; Li, Y-J.; Li, L-J. Anti-hepatitis B virus effect and possible mechanism of action of 3,4-o-dicaffeoylquinic Acid in vitro and in vivo. Evid. Based Complement. Alternat. Med., 2012, 356806, 2012.
[http://dx.doi.org/10.1155/2012/356806]
[108]
Vandyck, K.; Rudolf, B.; Chopped, G.Y.P.; Last, S.J.; Rombouts, G.; McGowan, D.C.; Verschueren, G.R.; Raboisson, P.J.B. Sulfamoylpyrrolamide derivatives and their use as medicaments for the treatment of hepatitis b. WO2014184350A1, 2021.
[109]
Liu, C.; Cai, D.; Zhang, L.; Tang, W.; Yan, R.; Guo, H.; Chen, X. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral Res., 2016, 134(2016), 97-107.2016.
[http://dx.doi.org/10.1016/j.antiviral.2016.08.026]
[110]
Lazar, C.; Durantel, D.; Macovei, A.; Zitzmann, N.; Zoulim, F.; Dwek, R.; Branzanichita, N. Treatment of hepatitis B virus-infected cells with α-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res., 2007, 76(1), 30-37.
[http://dx.doi.org/10.1016/j.antiviral.2007.04.004] [PMID: 17548120]
[111]
Hayakawa, M.; Umeyama, H.; Iwadate, M.; Taguchi, Y.H.; Yano, Y.; Honda, T.; Itami-Matsumoto, S.; Kozuka, R.; Enomoto, M.; Tamori, A.; Kawada, N.; Murakami, Y. Development of a novel anti-hepatitis B virus agent viaSp1. Sci. Rep., 2020, 10(1), 47.
[http://dx.doi.org/10.1038/s41598-019-56842-9] [PMID: 31913341]
[112]
Mak, L.Y.; Seto, W.K.; Yuen, M.F. Novel antivirals in clinical development for chronic hepatitis B infection. Viruses 13(2021), 1169, 2021.
[http://dx.doi.org/10.3390/v13061169]
[113]
Gane, E.; Locarini, S.; Lim, T.H.; Strasser, S.; Sievert, W.; Cheng, W.; Thompson, A.; Given, B.; Hamilton, M.; Biermer, R.; Kalmeijer, R.; Beumont-Mauviel, M.; Lenz, O.; Cloherty, G.; Wong, D.K.H.; Schwabe, C.; Jackson, K.; Ferrari, C.L.; Gish, R.G.; Yuen, M.F. Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. J. Hepatol., 2020, 73, S10.
[http://dx.doi.org/10.1016/S0168-8278(20)30597-3]
[114]
Kim, S.W.; Yoon, J.S.; Lee, M.; Cho, Y. Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus. Clin. Mol. Hepatol., 2022, 28(1), 17-30.
[http://dx.doi.org/10.3350/cmh.2021.0093] [PMID: 34281294]
[115]
Smith, E.S.; Whitty, E.; Yoo, B.; Moore, A.; Sempere, L.F.; Medarova, Z. Clinical applications of short non-coding rna-based therapies in the era of precision medicine. Cancers, 2022, 14(6), 1588.
[http://dx.doi.org/10.3390/cancers14061588] [PMID: 35326738]
[116]
Gupta, S.V.; Fanget, M.C.; MacLauchlin, C.; Clausen, V.A.; Li, J.; Cloutier, D.; Shen, L.; Robbie, G.J.; Mogalian, E. Clinical and preclinical single-dose pharmacokinetics of VIR-2218, an RNAi therapeutic targeting HBV infection. Drugs R D., 2021, 21(4), 455-465.
[http://dx.doi.org/10.1007/s40268-021-00369-w] [PMID: 34741731]
[117]
Yuen, M.F.; Heo, J.; Kumada, H.; Suzuki, F.; Suzuki, Y.; Xie, Q.; Jia, J.; Karino, Y.; Hou, J.; Chayama, K.; Imamura, M.; Lao-Tan, J.Y.; Lim, S.G.; Tanaka, Y.; Xie, W.; Yoon, J.H.; Duan, Z.; Kurosaki, M.; Park, S.J.; Labio, M.E.; Kumar, R.; Kweon, Y.O.; Yim, H.J.; Tao, Y.; Cremer, J.; Elston, R.; Davies, M.; Baptiste-Brown, S.; Han, K.; Campbell, F.M.; Paff, M.; Theodore, D. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J. Hepatol., 2022, 77(4), 967-977.
[http://dx.doi.org/10.1016/j.jhep.2022.05.031] [PMID: 35714812]
[118]
Yuen, M.F.; Heo, J.; Jang, J.W.; Yoon, J.H.; Kweon, Y.O.; Park, S.J.; Tami, Y.; You, S.; Yates, P.; Tao, Y.; Cremer, J.; Campbell, F.; Elston, R.; Theodore, D.; Paff, M.; Bennett, C.F.; Kwoh, T.J. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 27(2021), 1725-1734., 2021.
[http://dx.doi.org/10.1038/s41591-021-01513-4]
[119]
Gane, E.; Yuen, M.F.; Kim, D.J.; Chan, H.L.Y.; Surujbally, B.; Pavlovic, V.; Das, S.; Triyatni, M.; Kazma, R.; Grippo, J.F.; Buatois, S.; Lemenuel-Diot, A.; Krippendorff, B.F.; Mueller, H.; Zhang, Y.; Kim, H.J.; Leerapun, A.; Lim, T.H.; Lim, Y.S.; Tanwandee, T.; Kim, W.; Cheng, W.; Hu, T.H.; Wat, C. Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B. Hepatology, 2021, 74(4), 1795-1808.
[http://dx.doi.org/10.1002/hep.31920] [PMID: 34037271]
[120]
Curtil, C.; Enache, L.S.; Radreau, P.; Dron, A.G.; Scholtès, C.; Deloire, A.; Roche, D.; Lotteau, V.; André, P.; Ramière, C. The metabolic sensors FXRα, PGC‐1 α and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J., 2014, 28(3), 1454-1463.
[http://dx.doi.org/10.1096/fj.13-236372] [PMID: 24297698]
[121]
Singh, N.; Yadav, M.; Singh, A.K.; Kumar, H.; Dwivedi, S.K.D.; Mishra, J.S.; Gurjar, A.; Manhas, A.; Chandra, S.; Yadav, P.N.; Jagavelu, K.; Siddiqi, M.I.; Trivedi, A.K.; Chattopadhyay, N.; Sanyal, S. Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors. Mol. Endocrinol., 2014, 28(5), 659-673.
[http://dx.doi.org/10.1210/me.2013-1353] [PMID: 24597548]
[122]
Ali, A.H.; Carey, E.J.; Lindor, K.D. Recent advances in the development of farnesoid X receptor agonists. Ann. Transl. Med., 2015, 3(1), 5.
[http://dx.doi.org/10.3978/j.issn.2305-5839.2014.12.06] [PMID: 25705637]
[123]
Xu, J.; Gu, W.; Li, C.; Li, X.; Xing, G.; Li, Y.; Song, Y.; Zheng, W. Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha. J. Nat. Med., 2016, 70(3), 584-591.
[http://dx.doi.org/10.1007/s11418-016-0980-6] [PMID: 26968537]
[124]
Joly, S.; Porcherot, M.; Radreau, P.; Vonderscher, J.; André, P.; Meldrum, E.; Arold, G. Van de Wetering de Rooij, J.; Staner, C.; Laveille, C.; Scalfaro, P. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J. Hepatol., 2017, 66(1), S690.
[http://dx.doi.org/10.1016/S0168-8278(17)31853-6]
[125]
Ebert, G.; Allison, C.; Preston, S.; Cooney, J.; Toe, J.G.; Stutz, M.D.; Ojaimi, S.; Baschuk, N.; Nachbur, U.; Torresi, J.; Silke, J.; Begley, C.G.; Pellegrini, M. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc. Natl. Acad. Sci. USA, 2015, 112(18), 5803-5808.
[http://dx.doi.org/10.1073/pnas.1502400112] [PMID: 25902530]
[126]
Ebert, G.; Preston, S.; Allison, C.; Cooney, J.; Toe, J.G.; Stutz, M.D.; Ojaimi, S.; Scott, H.W.; Baschuk, N.; Nachbur, U.; Torresi, J.; Chin, R.; Colledge, D.; Li, X.; Warner, N.; Revill, P.; Bowden, S.; Silke, J.; Begley, C.G.; Pellegrini, M. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc. Natl. Acad. Sci. USA, 2015, 112(18), 5797-5802.
[http://dx.doi.org/10.1073/pnas.1502390112] [PMID: 25902529]
[127]
Kayesh, M.E.H.; Kohara, M.; Tsukiyama-Kohara, K. Toll-like receptor response to hepatitis B virus infection and potential of tlr agonists as immunomodulators for treating chronic hepatitis B: An overview. Int. J. Mol. Sci., 2021, 22(19), 10462.
[http://dx.doi.org/10.3390/ijms221910462] [PMID: 34638802]
[128]
Herschke, F.; Li, C.; Zhu, R.; Han, Q.; Wu, Q.; Lu, Q.; Barale-Thomas, E.; De Jonghe, S.; Lin, T.I.; De Creus, A. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice vianon-cytolytic mechanisms. Antiviral Res., 2021, 196105196
[http://dx.doi.org/10.1016/j.antiviral.2021.105196] [PMID: 34718044]
[129]
Luk, A.; Jiang, Q.; Glavini, K.; Triyatni, M.; Zhao, N.; Racek, T.; Zhu, Y.; Grippo, J.F. A single and multiple ascending dose study of toll-like receptor 7 Agonist (RO7020531) in Chinese healthy volunteers. Clin. Transl. Sci., 2020, 13(5), 985-993.
[http://dx.doi.org/10.1111/cts.12791] [PMID: 32268000]
[130]
Daffis, S.; Balsitis, S.; Chamberlain, J.; Zheng, J.; Santos, R.; Rowe, W.; Ramakrishnan, D.; Pattabiraman, D.; Spurlock, S.; Chu, R.; Kang, D.; Mish, M.; Ramirez, R.; Li, L.; Li, B.; Ma, S.; Hung, M.; Voitenleitner, C.; Yon, C.; Suresh, M.; Menne, S.; Cote, P.; Delaney, W.E., IV; Mackman, R.; Fletcher, S.P. Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B. Hepatology, 2021, 73(1), 53-67.
[http://dx.doi.org/10.1002/hep.31255] [PMID: 32246499]
[131]
Pichlmair, A.; Schulz, O.; Tan, C.P.; Näslund, T.I.; Liljeström, P.; Weber, F.; Reis e Sousa, C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science, 2006, 314(5801), 997-1001.
[http://dx.doi.org/10.1126/science.1132998] [PMID: 17038589]
[132]
Korolowicz, K.E.; Iyer, R.P.; Czerwinski, S.; Suresh, M.; Yang, J.; Padmanabhan, S.; Sheri, A.; Pandey, R.K.; Skell, J.; Marquis, J.K.; Kallakury, B.V.; Tucker, R.D.; Menne, S. Antiviral efficacy and host innate immunity associated with sb 9200 treatment in the woodchuck model of chronic hepatitis B. PLoS One, 2016, 11(8)e0161313
[http://dx.doi.org/10.1371/journal.pone.0161313] [PMID: 27552102]
[133]
Ye, B.; Liu, X.; Li, X.; Kong, H.; Tian, L.; Chen, Y. T-cell exhaustion in chronic hepatitis B infection: Current knowledge and clinical significance. Cell Death Dis., 2015, 6(3)e1694
[http://dx.doi.org/10.1038/cddis.2015.42] [PMID: 25789969]
[134]
Cai, H.; Liu, G.; Zhong, J.; Zheng, K.; Xiao, H.; Li, C.; Song, X.; Li, Y.; Xu, C.; Wu, H.; He, Z.; Zhu, Q. Immune checkpoints in viral infections. Viruses, 2020, 12(9), 1051.
[http://dx.doi.org/10.3390/v12091051] [PMID: 32967229]
[135]
Boni, C.; Fisicaro, P.; Valdatta, C.; Amadei, B.; Di Vincenzo, P.; Giuberti, T.; Laccabue, D.; Zerbini, A.; Cavalli, A.; Missale, G.; Bertoletti, A.; Ferrari, C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol., 2007, 81(8), 4215-4225.
[http://dx.doi.org/10.1128/JVI.02844-06] [PMID: 17287266]
[136]
Nebbia, G.; Peppa, D.; Schurich, A.; Khanna, P.; Singh, H.D.; Cheng, Y.; Rosenberg, W.; Dusheiko, G.; Gilson, R. ChinAleong, J.; Kennedy, P.; Maini, M.K. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One, 2012, 7(10)e47648
[http://dx.doi.org/10.1371/journal.pone.0047648] [PMID: 23112829]
[137]
Wu, W.; Shi, Y.; Li, S.; Zhang, Y.; Liu, Y.; Wu, Y.; Chen, Z. Blockade of Tim-3 signaling restores the virus-specific CD8 + T-cell response in patients with chronic hepatitis B. Eur. J. Immunol., 2012, 42(5), 1180-1191.
[http://dx.doi.org/10.1002/eji.201141852] [PMID: 22539292]
[138]
Ye, B.; Li, X.; Dong, Y.; Wang, Y.; Tian, L.; Lin, S.; Liu, X.; Kong, H.; Chen, Y. Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B. Medicine, 2017, 96(1)e5275
[http://dx.doi.org/10.1097/MD.0000000000005275] [PMID: 28072682]
[139]
Zhang, Z.; Zhang, J.Y.; Wherry, E.J.; Jin, B.; Xu, B.; Zou, Z.S.; Zhang, S.Y.; Li, B.S.; Wang, H.F.; Wu, H.; Lau, G.K.K.; Fu, Y.X.; Wang, F.S. Dynamic programmed death 1 expression by virusspecific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology, 2008, 134(7), 1938-1949.e3, 1949.e1- 1949.e3.
[http://dx.doi.org/10.1053/j.gastro.2008.03.037] [PMID: 18455515]
[140]
Liu, J.; Zhang, E.; Ma, Z.; Wu, W.; Kosinska, A.; Zhang, X.; Möller, I.; Seiz, P.; Glebe, D.; Wang, B.; Yang, D.; Lu, M.; Roggendorf, M. Enhancing virus-specific immunity in vivoby combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog., 2014, 10(1)e1003856
[http://dx.doi.org/10.1371/journal.ppat.1003856] [PMID: 24391505]
[141]
Gane, E.; Verdon, D.J.; Brooks, A.E.; Gaggar, A.; Nguyen, A.H.; Subramanian, G.M.; Schwabe, C.; Dunbar, P.R. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J. Hepatol., 2019, 71(5), 900-907.
[http://dx.doi.org/10.1016/j.jhep.2019.06.028] [PMID: 31306680]
[142]
Zhang, X.; Zhou, Y.; Chen, C.; Fang, W.; Cai, X.; Zhang, X.; Zhao, M.; Zhang, B.; Jiang, W.; Lin, Z.; Ma, Y.; Yang, Y.; Huang, Y.; Zhao, H.; Xu, R.; Hong, S.; Zhang, L. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J. Immunother. Cancer, 2019, 7(1), 322.
[http://dx.doi.org/10.1186/s40425-019-0808-5] [PMID: 31753012]
[143]
Akbar, S.M.F.; Al Mahtab, M.; Aguilar, J.C.; Yoshida, O.; Penton, E.; Gerardo, G.N.; Hiasa, Y. Sustained antiviral and liver protection by a nasal therapeutic vaccine (NASVAC, Containing Both HBsAg and HBcAg) in patients with chronic hepatitis b: 2-year follow-up of phase III clinical trial. Pathogens, 2021, 10(11), 1440.
[http://dx.doi.org/10.3390/pathogens10111440] [PMID: 34832596]
[144]
Martin, P.; Dubois, C.; Jacquier, E.; Dion, S.; Mancini-Bourgine, M.; Godon, O.; Kratzer, R.; Lelu-Santolaria, K.; Evlachev, A.; Meritet, J.F.; Schlesinger, Y.; Villeval, D.; Strub, J.M.; Van Dorsselaer, A.; Marchand, J.B.; Geist, M.; Brandely, R.; Findeli, A.; Boukhebza, H.; Menguy, T.; Silvestre, N.; Michel, M.L.; Inchauspé, G. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut, 2015, 64(12), 1961-1971.
[http://dx.doi.org/10.1136/gutjnl-2014-308041] [PMID: 25429051]
[145]
Zoulim, F.; Fournier, C.; Habersetzer, F.; Sprinzl, M.; Pol, S.; Coffin, C.S.; Leroy, V.; Ma, M.; Wedemeyer, H.; Lohse, A.W.; Thimme, R.; Lugardon, K.; Martin, P.; Bastien, B.; Sansas, B.; Adda, N.; Halluard, C.; Bendjama, K.; Brandely, M.; Inchauspé, G. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: A phase 1b placebo-controlled trial. Hum. Vaccin. Immunother., 2020, 16(2), 388-399.
[http://dx.doi.org/10.1080/21645515.2019.1651141] [PMID: 31373537]
[146]
Boni, C.; Janssen, H.L.A.; Rossi, M.; Yoon, S.K.; Vecchi, A.; Barili, V.; Yoshida, E.M.; Trinh, H.; Rodell, T.C.; Laccabue, D.; Alfieri, A.; Brillo, F.; Fisicaro, P.; Acerbi, G.; Pedrazzi, G.; Andreone, P.; Cursaro, C.; Margotti, M.; Santoro, R.; Piazzolla, V.; Brunetto, M.R.; Coco, B.; Cavallone, D.; Zhao, Y.; Joshi, A.; Woo, J.; Lau, A.H.; Gaggar, A.; Subramanian, G.M.; Massetto, B.; Fung, S.; Ahn, S.H.; Ma, X.; Mangia, A.; Ferrari, C. Combined GS-4774 and tenofovir therapy can improve HBV-specific t-cell responses in patients with chronic hepatitis. Gastroenterol., 2019, 157(1), 227-241.e7.
[http://dx.doi.org/10.1053/j.gastro.2019.03.044] [PMID: 30930022]
[147]
Chinnakannan, S.K.; Cargill, T.N.; Donnison, T.A.; Ansari, M.A.; Sebastian, S.; Lee, L.N.; Hutchings, C.; Klenerman, P.; Maini, M.K.; Evans, T.; Barnes, E. The design and development of a multi-hbv antigen encoded in chimpanzee adenoviral and modified vaccinia ankara viral vectors; a novel therapeutic vaccine strategy against HBV. Vaccines, 2020, 8(2), 184.
[http://dx.doi.org/10.3390/vaccines8020184] [PMID: 32295168]
[148]
Cargill, T.; Barnes, E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin. Exp. Immunol., 2021, 205(2), 106-118.
[http://dx.doi.org/10.1111/cei.13614] [PMID: 33969474]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy